Standout Papers

Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in A... 2018 2026 2020 2023 697
  1. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients (2018)
    Victoria Chernyak, Kathryn J. Fowler et al. Radiology
  2. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2019)
    Stephen A. Harrison, Mustafa R. Bashir et al. The Lancet
  3. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2018)
    Stephen A. Harrison, Mary E. Rinella et al. The Lancet
  4. Deep learning in radiology: An overview of the concepts and a survey of the state of the art with focus on MRI (2018)
    Maciej A. Mazurowski, Mateusz Buda et al. Journal of Magnetic Resonance Imaging
  5. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis (2020)
    Stephen A. Harrison, Guy Neff et al. Gastroenterology
  6. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial (2023)
    Stephen A. Harrison, Rebecca Taub et al. Nature Medicine

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 75 standout
Sub-graph 1 of 16

Citing Papers

Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis
2025 Standout
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
2024 Standout
12 intermediate papers

Works of Mustafa R. Bashir being referenced

Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
2023
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2019 Standout
and 12 more

Author Peers

Author Last Decade Papers Cites
Mustafa R. Bashir 3604 4362 3796 225 9.1k
Kathryn J. Fowler 2240 2683 3342 220 6.2k
Boris Guiu 1209 1727 2561 224 6.2k
Ihab R. Kamel 4460 4903 4984 401 17.0k
Takamichi Murakami 4055 3672 5053 420 10.4k
Michael S. Middleton 1893 5475 2795 102 7.4k
Dushyant V. Sahani 3695 2985 2209 218 12.6k
Yuko Kono 1474 2447 2730 116 4.9k
Evan S. Siegelman 2050 1245 1054 172 8.4k
Jean-François H. Geschwind 2573 2231 5781 173 11.0k
Vivian S. Lee 5565 1366 1459 182 8.9k

All Works

Loading papers...

Rankless by CCL
2026